Physician profile
David Joel Korman
NPI 1942204755
$11,226.57
in general payments reported to CMS, 2019-2025
24 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $1,023 · 2021: $1,361 · 2022: $1,718 · 2023: $1,793 · 2024: $1,643 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,193 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,192.96 |
| Education | $327.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,777.93 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,232.49 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,224.47 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,125.88 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $1,056.65 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $833.72 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $787.60 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $666.18 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $397.76 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $373.28 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $278.70 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $253.47 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $236.52 | 2019-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $206.81 | 2019-2022 | |
| Indivior INC. | $153.53 | 2019-2024 | Perseris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $118.98 | 2019-2021 | |
| Bausch Health US, LLC | $115.96 | 2021-2023 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $112.19 | 2019-2021 | |
| Eisai INC. | $90.71 | 2020-2022 | |
| Glaxosmithkline, LLC. | $59.44 | 2021-2023 | Benlysta |
| Almatica Pharma LLC | $51.28 | 2023-2024 | Loreev Xr |
| Brainsway USA INC | $34.19 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.74 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.09 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Korman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.